YKYuko Kataoka

Yuko Kataoka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuko Kataoka has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy

    by Yuko Kataoka, Ryoji Goto, Yoshikazu Chishiki, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Sho Moriguchi, Yuki Momota, Tetsuji Kamada, et al.

  • Open Access

    Spatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau ( 18F ) Positron Emission T omography

    by Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada, et al.

    Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high‐contrast in vivo detection of four‐repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: Twenty‐six patients with PSP (18 Richardson's syndrome [PSP‐RS], 8 non‐RS) and 10 age‐ and sex‐matched healthy controls (HCs) underwent florzolotau PET, magnetic resonance imaging, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVRs) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellar white matter, and minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP‐RS and a univariate correlation (Spearman's ρ = 0.688, P = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to increase with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau‐targeted therapeutic trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Distinct tau pathologies in the nucleus basalis of Meynert between early-onset and late-onset Alzheimer's disease patients revealed by positron emission tomography

    by Hisaomi Suzuki, Kenji Tagai, Maiko Ono, Hiroshi Shimizu, Hironobu Endo, Hideki Matsumoto, Manabu Kubota, Yuko Kataoka, Sho Moriguchi, Shin Kurose, et al.

    Background: Tau accumulation in the nucleus basalis of Meynert (nbM) has been documented in Alzheimer's disease (AD), but its relationship to neuropathological changes in other brain regions and cognitive deficits remains unclear, particularly between early-onset AD (EOAD) and late-onset AD (LOAD). Objective: To evaluate tau accumulation patterns in the nbM and other brain regions in EOAD and LOAD using 18 F-florzolotau PET and examine correlations with cognitive function. Methods: Thirty-eight amyloid-positive AD patients (15 EOAD, 23 LOAD) and 46 healthy controls underwent 18 F-florzolotau PET. Tau levels were quantified in the nbM and Braak-staging regions. Postmortem brain samples were examined to assess 18 F-florzolotau binding to tau deposits. Results: EOAD showed a higher overall tau burden, including in the nbM, compared with LOAD. However, nbM tau levels correlated more strongly with cognitive decline in LOAD than EOAD. The relationship between nbM tau and neocortical tau differed between EOAD and LOAD. Histopathology revealed abundant 18 F-florzolotau labeling of neurofibrillary tangles (NFTs) and ghost tangles in AD nbM samples. Conclusions: This study provides the first in vivo PET evidence of differential nbM tau pathology between EOAD and LOAD, with higher accumulation but weaker correlation to cognition in EOAD. The distinct relationships between nbM and cortical tau in EOAD and LOAD suggest divergent pathological trajectories. 18 F-florzolotau PET successfully visualized NFTs and extracellular ghost tangles in the nbM across AD stages. These findings highlight the importance of considering age of onset when evaluating tau pathology and its clinical correlates in AD.


  • Open Access

    Early vascular responses to abluminal biodegradable polymer-coated versus circumferential durable polymer-coated newer-generation drug-eluting stents in humans: a pathologic study

    by Y Kawagoe, F Otuka, D Onozuka, H Ueda, Y Ikeda, K Ogo, M Matsumoto, K Amemiya, Y Asaumim, Y Kataoka, et al.

    Background: Recent clinical trials are testing strategies for short (1–3 months) dual antiplatelet therapy (DAPT) following newer-generation drug-eluting stent (DES) placement. However, the safety of short DAPT regimens is not supported by biological evidence in humans. Purpose: We sought to evaluate early pathologic responses to newer-generation DES by comparing abluminal biodegradable polymer-coated DES (BP-DES) with circumferential durable polymer-coated DES (DP-DES) in human autopsy cases. Methods: The study included a total of 37 coronary lesions with thin strut newer-generation DES (DP-DES=23 [XIENCE=18, Resolute Integrity=5] and BP-DES=14 [SYNERGY=9, Ultimaster=5]) with duration of implantation <90 days in 25 autopsy cases. The process of stent healing was precisely evaluated for every single strut in association with underlying tissue characteristics. The degree of strut coverage was defined as follows: grade 0 (bare struts), grade 1 (struts covered with thrombus, fibrin, or other tissues or cells without endothelium), grade 2 (struts covered with single-layered endothelium without underlying smooth muscle cell layers), and grade 3 (struts covered with endothelium and underlying smooth muscle cell layers) (Figure 1). Results: Duration of implantation was similar in lesions with DP-DES and those with BP-DES (median=20 vs. 17 days). A total of 1986 struts (DP-DES=1261, BP-DES=725) were pathologically analyzed. Focal grade 2 coverage was observed as early as 5 days after the implantation in both stents. Multilevel mixed-effects ordered logistic regression model demonstrated that BP-DES exhibited greater strut coverage compared with DP-DES (odds ratio; 3.50, 95% CI; 1.31–9.41, P=0.013), which remained significant after adjustment for duration of implantation and underlying tissue characteristics (odds ratio; 2.64, 95% CI; 1.04–6.68, P=0.040). The time course of vessel healing assessed as predictive probability of strut coverage (grade 0–3) stratified by duration of implantation is shown in Figure 2. Predictive probability of grade 2 and 3 coverage was comparably limited at 30 days (DP-DES=17.7% vs. BP-DES=29.0%) and increased at 90 days (DP-DES=76.1% vs. BP-DES=85.9%). Both stents showed few inflammation and similar degree of fibrin deposition. Conclusions: The current first pathologic study on early biological responses to newer-generation DES in humans demonstrated that single-layered endothelial coverage begins in days following the stent placement, and abluminal BP-DES potentially exhibit faster strut coverage with smooth muscle cell infiltration than circumferential DP-DES. Nevertheless, vessel healing remains suboptimal at 30 days in both DP- and BP-DES, which progresses with time to become substantial at 90 days. Our results suggest that very short duration of DAPT for 1 month should be applied with caution, taking into account the trade-off between bleeding and thrombotic risks. Funding Acknowledgement: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Grant-in-Aid for Scientific Research (C) from the Japan Society for the Promotion of Science


  • Histopathological analysis of retrieved thrombi from patients with acute ischemic stroke with malignant tumors

    by Yuko Kataoka, Kazutaka Sonoda, Jun C Takahashi, Hatsue Ishibashi-Ueda, Kazunori Toyoda, Yusuke Yakushiji, Hirofumi Kusaka, Masatoshi Koga

    Background The procoagulant state in cancer increases the thrombotic risk, and underlying cancer could affect treatment strategies and outcomes in patients with ischemic stroke. However, the histopathological characteristics of retrieved thrombi in patients with cancer have not been well studied. This study aimed to assess the histopathological difference between thrombi in patients with and without cancer. Methods We studied consecutive patients with acute major cerebral artery occlusion who were treated with endovascular therapy between October 2010 and December 2016 in our single-center registry. The retrieved thrombi were histopathologically investigated with hematoxylin and eosin and Masson’s trichrome staining. The organization and proportions of erythrocyte and fibrin/platelet components were studied using a lattice composed of 10×10 squares. Results Of the 180 patients studied, 17 (8 women, age 76.5±11.5 years) had cancer and 163 (69 women, age 74.1±11.2 years) did not. Those with cancer had a higher proportion of fibrin/platelets (56.6±27.4% vs 40.1±23.9%, p=0.008), a smaller proportion of erythrocytes (42.1±28.3% vs 57.5±25.1%, p=0.019), and higher serum D-dimer levels (5.9±8.2 vs 2.4±4.3 mg/dL, p=0.005) compared with the non-cancer cases. Receiver operating characteristic curve analysis showed the cut-off ratio of fibrin/platelet components related to cancer was 55.7% with a sensitivity of 74.8%, specificity 58.8% and area under the curve (AUC) value of 0.67 (95% CI 0.53 to 0.81), and the cut-off ratio of erythrocyte components was 44.7% with a sensitivity of 71.2%, specificity 58.9% and AUC value of 0.66 (95% CI 0.51 to 0.80). Conclusions Thromboemboli of major cerebral arteries in patients with cancer were mainly composed of fibrin/platelet-rich components.


  • Open Access

    Survey of Problems in School Life in People with Bilateral Hearing Loss

    by Yuko Kataoka, Akiko Sugaya, Atsuko Nakagawa, Satomi Tanaka, Naomi Toida, Kunihiro Fukushima, Yukihide Maeda, Shin Kariya

    要旨: 先天性難聴の早期発見,早期療育, 人工内耳手術の低年齢化などに伴い, 難聴児の聴取能, 言語発達は向上し, 近年地域の学校でインクルーシブ教育を受ける者が増加しているが, それに伴う問題も挙げられている。我々は, 小学校5年生以上25歳未満のインクルーシブ教育を受けた経験のある両側難聴者89名に, 学校生活で抱える問題に関して質問紙での実態把握調査を実施した。 対象者の多くは, 授業中の支障に加え, グループ学習や雑音下, 距離が離れた場所からの聞き取りの支障を抱えており, また英語, 音楽, 体育をはじめとする教科学習での課題や, 友人関係での問題も挙げていた。難聴の程度が重いほど頻度が高い傾向がみられた。 個々の学校生活における状況と問題を正確に把握した上で, 視覚情報を用いたコミュニケーション, 支援員の配属, 学習面でのサポート, 専門家による心理的負担へのアプローチといった個々に対応した介入の必要性が示唆される。


  • Steroid-dependent sensorineural hearing loss in a patient with Charcot-Marie-Tooth disease showing auditory neuropathy

    by Yukihide Maeda, Yuko Kataoka, Akiko Sugaya, Shin Kariya, Katsuhiro Kobayashi, Kazunori Nishizaki


  • Open Access

    The Age at Which the Grade of Special Child Dependent^|^apos;s Allowance Act Can Be Judged in the Case of Deaf Children

    by Yuko Kataoka, Kunihiro Fukushima, Akiko Sugaya, Yukihide Maeda, Kazunori Nishizaki

    近年新生児聴覚スクリーニングの普及により, 難聴児の多くは生後数カ月のうちに診断され, 療育を開始している. 一方, 特別児童扶養手当に関してはオージオメーターによる検査が可能となるまで受給されず, 診断から受給までの間に年単位の時間差が生じているのが現状である. われわれは, 生後12カ月までに ABR を実施し, 両耳 90dBnHL で無反応であった児の聴力経過の検討を行った. その結果, 聴覚障害単独の児では特別児童扶養手当に該当するか否かは1歳時点で可能であるが, 等級の判定は1歳で慎重な判断が必要であること, また重複障害をもつ児は検査を繰り返し慎重に診断する必要があるが特別児童扶養手当の判定は可能であると判断した.